| ID | 10118 |
| Vaccine Name | Lyssavac N |
| Disease Name | Rabies |
| Disease Classification | Neurologic |
| Virus Name | Rabies virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | Zydus Candila Healthcare Limited |
| Year of Manufacturing | NA |
| Manufacturing Country | India |
| Age | NA |
| Dosage | 3 doses on day 0, 7 and 21 |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | Purified duck embryo cell |
| Approving Organisation | WHO |
| Collaborating Organisation | Berna Biotech |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://www.fda.moph.go.th/sites/drug/Summary/1C_278_50_Lyssavac%20N%20Injection.pdf |
| Additional Links | https://www.livemint.com/Companies/XopdfNnBp4Y6189QY3PY2N/Zydus-Cadila-receives-WHO-nod-for-rabies-vaccine.html
|